Samsung Biologics (KS:207940) unveiled a CHF 1.46 billion ($1.8 billion) all-cash bid for Swiss peptide specialist PolyPeptide Group (SIX:PPGN) on Monday, sending its own shares down 3.4% as investors weighed the cost of the South Korean contract manufacturer’s largest-ever overseas acquisition.
The deal marks a strategic pivot into one of biopharma’s fastest-expanding segments – peptide-based GLP-1 therapies for obesity and diabetes – directly challenging established contract manufacturers already servicing Novo Nordisk and Eli Lilly supply chains.
Key Takeaways
- All-cash offer of CHF 44.31 per share, a 6.1% premium to Friday’s close
- Deal would be South Korea’s largest-ever biopharma cross-border acquisition
- Shareholders holding ~55.65% of PolyPeptide shares have agreed to tender
Market Reaction & Context
Samsung Biologics fell 3.4% to KRW 1,354,000 in Seoul on Monday, a comparatively contained move given that the broader KOSPI index dropped 4.1% on the same session 1. PolyPeptide shares were indicated sharply higher after the tender offer was made public, reflecting the 6.1% control premium embedded in the CHF 44.31 per-share price 2.
The bid arrives amid an accelerating wave of M&A in the contract development and manufacturing organisation (CDMO) space, as drug companies race to lock in capacity for GLP-1 active pharmaceutical ingredients (APIs). Cross-sector deal velocity has picked up broadly in 2026, with acquirers willing to pay strategic premiums for specialised manufacturing platforms.
Deal Structure & Strategic Rationale
Under the public tender offer, Samsung Biologics will pay CHF 44.31 per share in cash for all outstanding PolyPeptide stock, valuing the Baar, Switzerland-headquartered company at approximately CHF 1.46 billion 1. The transaction is subject to regulatory approvals and other customary closing conditions, with completion targeted before the end of 2026.
PolyPeptide, spun off from global pharmaceutical company Ferring in 1996, has developed and produced more than 1,000 therapeutic peptides across manufacturing sites in Sweden, Belgium, France, the United States and India. Adding those facilities significantly diversifies Samsung Biologics’ geographic footprint beyond its existing South Korean base, which is centred on antibody drugs and antibody-drug conjugates.
The South Korean firm said the acquisition directly addresses growing client demand for peptide-based GLP-1 therapies – medicines made from short amino-acid chains that mimic natural hormones to reduce appetite and regulate blood sugar – as the global obesity drug market continues to expand at a rapid pace 2.
Board Support & Shareholder Commitments
PolyPeptide’s board unanimously recommended the offer, and shareholders representing approximately 55.65% of outstanding shares have already committed to tender, effectively providing deal certainty well above most tender-offer thresholds 2. The level of pre-committed support reduces completion risk materially, analysts noted.
“After a comprehensive review of strategic options, the Board is convinced that Samsung Biologics’ offer is compelling for our shareholders, delivering an attractive cash price and immediate, certain value today,” said Peter Wilden, chairman of PolyPeptide 1.
Competitive Positioning
Samsung Biologics said the combined entity would be positioned to serve a broader range of therapeutic modalities, adding peptide API manufacturing to its existing large-molecule biologics platform 1. The company described the transaction as the largest biopharmaceutical M&A deal in South Korea’s history – a claim that underscores how aggressively Korean CDMOs are seeking to close the capability gap with Western rivals such as Lonza and Catalent.
Peptide manufacturing capacity has become a strategic chokepoint as drugmakers scale up GLP-1 production; securing a platform with PolyPeptide’s multi-site network and decade-long customer relationships could provide Samsung Biologics with a durable competitive moat in that segment.
Outlook
The deal is expected to close by year-end 2026, pending regulatory sign-off across multiple jurisdictions given PolyPeptide’s international manufacturing presence 2. Samsung Biologics has not provided integration-cost guidance or synergy targets, leaving analysts to assess the transaction’s financial impact on the group’s near-term earnings profile.
With GLP-1 demand showing no signs of plateauing, the strategic logic appears clear – but the all-cash structure means Samsung Biologics will need to demonstrate swift revenue contributions from the new peptide platform to justify the price paid to a market already cautious about deal-driven dilution.
Not investment advice. For informational purposes only.
References
1Jenny Lee (2026-07-20). “Samsung Biologics makes $1.8 billion all-cash offer for Switzerland’s PolyPeptide Group”. CNBC. Retrieved 2026-07-20.
2Roushni Nair (2026-07-20). “Samsung Biologics bids $1.8 bln for PolyPeptide, shares fall 3%”. Investing.com. Retrieved 2026-07-20.
3(2026-07-19). “Samsung Biologics Agrees to Buy PolyPeptide in $1.8 Billion Deal”. Bloomberg. Retrieved 2026-07-20.
4CNBC (2026-07-20). “Samsung Biologics makes $1.8 billion all-cash offer for Switzerland’s PolyPeptide Group”. LinkedIn/CNBC. Retrieved 2026-07-20.